Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
ADCC-activating antibodies correlate with decreased risk of congenital human cytomegalovirus transmission
Eleanor C. Semmes, … , Justin Pollara, Sallie R. Permar
Eleanor C. Semmes, … , Justin Pollara, Sallie R. Permar
Published July 10, 2023
Citation Information: JCI Insight. 2023;8(13):e167768. https://doi.org/10.1172/jci.insight.167768.
View: Text | PDF
Research Article Immunology Infectious disease

ADCC-activating antibodies correlate with decreased risk of congenital human cytomegalovirus transmission

  • Text
  • PDF
Abstract

Human cytomegalovirus (HCMV) is the most common vertically transmitted infection worldwide, yet there are no vaccines or therapeutics to prevent congenital HCMV (cCMV) infection. Emerging evidence indicates that antibody Fc effector functions may be a previously underappreciated component of maternal immunity against HCMV. We recently reported that antibody-dependent cellular phagocytosis (ADCP) and IgG activation of FcγRI/FcγRII were associated with protection against cCMV transmission, leading us to hypothesize that additional Fc-mediated antibody functions may be important. In this same cohort of HCMV-transmitting (n = 41) and nontransmitting (n = 40) mother-infant dyads, we report that higher maternal sera antibody–dependent cellular cytotoxicity (ADCC) activation is also associated with lower risk of cCMV transmission. We investigated the relationship between ADCC and IgG responses against 9 viral antigens and found that ADCC activation correlated most strongly with sera IgG binding to the HCMV immunoevasin protein UL16. Moreover, we determined that higher UL16-specific IgG binding and FcγRIII/CD16 engagement were associated with the greatest risk reduction in cCMV transmission. Our findings indicate that ADCC-activating antibodies against targets such as UL16 may represent an important protective maternal immune response against cCMV infection that can guide future HCMV correlates studies and vaccine or antibody-based therapeutic development.

Authors

Eleanor C. Semmes, Itzayana G. Miller, Nicole Rodgers, Caroline T. Phan, Jillian H. Hurst, Kyle M. Walsh, Richard J. Stanton, Justin Pollara, Sallie R. Permar

×

Figure 2

HCMV-specific NK cell ADCC and FcγRIII/CD16 activating antibodies cluster with anti-UL16 and anti-UL141 IgG responses.

Options: View larger image (or click on image) Download as PowerPoint
HCMV-specific NK cell ADCC and FcγRIII/CD16 activating antibodies cluste...
Hierarchical clustering was performed on Spearman correlation coefficients to group strongly correlated immune variables. Matrix of maternal sera antibody responses showing Spearman correlation coefficients from –1.0 (blue) to +1.0 (red). Nonsignificant correlations (P > 0.05) shown in white. MFI, mean florescent intensity; level, total antigen-specific IgG binding measured by a binding antibody multiplex assay; gB-transfected cell IgG, IgG binding to cell-associated gB as measured in ref. 7.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts